Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.

Summary: Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.

Summary: Catalent experts Ann McMahon and Pamela Barton share examples where integrated drug product and clinical supply services enabled a client to expedite timelines or avoid costly errors.

Summary: This webinar discusses the challenges associated with pandemic drug manufacture and the extent to which vials that store vaccines could become a constraint, as well as the requirements that are needed in delivery systems and cold chain logistics.

Summary: Enzymes can be challenging to express and scale up to become biologic therapies.  In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke...

Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with...

Summary: Which 11 biotech startups stand out from the pack that have launched in 2020? Watch the Endpoints 11 - Startups to Watch Awards, a virtual event celebrating innovative science and entrepreneurship.

Summary: Learn about the complexities from raw material supply through drug product manufacturing, including planning early for a commercial-ready process.

Summary: In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies and the various solutions available for commercial scale-up of advanced therapeutics